Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer

BMC Urology

Volumn 13, Issue , 2013, Pages

  Boman, Karolina ^a   Segersten, Ulrika ^b   Ahlgren, Göran ^a   Eberhard, Jakob ^a   Uhlén, Mathias ^c,d   Jirström, Karin ^a   Malmström, Per Uno ^b  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Prognosis; RBM3; Urothelial bladder cancer

Indexed keywords

RNA BINDING MOTIF PROTEIN 3; RNA BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; UROTHELIAL BLADDER CANCER;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84875819478     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-13-17     Document Type: Article

References (22)

1. Biology and management of bladder cancer. Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie JP, N Engl J Med 1990 322 16 1129 1138 10.1056/NEJM199004193221607 2181313 (Pubitemid 20149531)
2. T1G3 bladder cancer-indications for early cystectomy. Masood S, Sriprasad S, Palmer JH, Mufti GR, Int Urol Nephrol 2004 36 1 41 44 15338671 (Pubitemid 38864807)
3. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Lebret T, Watson RW, Molinie V, Poulain JE, O'Neill A, Fitzpatrick JM, Botto H, Eur Urol 2007 51 1 161 166 discussion 166-167 10.1016/j.eururo.2006.06.006 16828965 (Pubitemid 44821520)
4. The treatment of advanced bladder cancer. Sternberg CN, Ann Oncol 1995 6 2 113 126 7786818
5. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Soloway MS, Lopez AE, Patel J, Lu Y, Cancer 1994 73 7 1926 1931 10.1002/1097-0142(19940401)73:7<1926::AID- CNCR2820730725>3.0.CO;2-Q 8137219 (Pubitemid 24101973)
6. High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer. Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Ponten F, Johannesson H, Smaragdi K, Frantz C, Proteomics Clin Appl 2011 5 11-12 624 635 21956899
7. Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Jogi A, Brennan DJ, Ryden L, Magnusson K, Ferno M, Stal O, Borgquist S, Uhlen M, Landberg G, Pahlman S, Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc 2009 22 12 1564 1574 10.1038/modpathol.2009.124
8. Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: an analysis of 215 cases from the Malmo Diet and Cancer Study. Jonsson L, Bergman J, Nodin B, Manjer J, Ponten F, Uhlen M, Jirstrom K, J Transl Med 2011 9 114 10.1186/1479-5876-9-114 21777469
9. High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Jonsson L, Gaber A, Ulmert D, Uhlen M, Bjartell A, Jirstrom K, Diagn Pathol 2011 6 91 10.1186/1746-1596-6-91 21955582
10. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, J Transl Med 2010 8 78 10.1186/1479-5876-8-78 20727170
11. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K, Translational oncology 2011 4 4 212 221 21804916
12. Noninvasive urothelial neoplasias; WHO classification of noninvasive papillary urothelial tumours. Sauter GAF, Amin MB, A World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs Lyon: IARCC, In Elbe JN EJ, Sesterhenn I, 2004
13. Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Sureban SM, Ramalingam S, Natarajan G, May R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK, Brackett DJ, Postier RG, Oncogene 2008 27 33 4544 4556 10.1038/onc.2008.97 18427544
14. The RNA-binding protein RBM3 is required for cell proliferation and protects against serum deprivation-induced cell death. Wellmann S, Truss M, Bruder E, Tornillo L, Zelmer A, Seeger K, Buhrer C, Pediatr Res 2010 67 1 35 41 10.1203/PDR.0b013e3181c13326 19770690
15. DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J, Int J Androl 2007 30 4 282 291 discussion 291 10.1111/j.1365-2605.2007.00772.x 17573848
16. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Nature 2005 434 7035 864 870 10.1038/nature03482 15829956 (Pubitemid 40558993)
17. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA, J Clin Oncol 1992 10 7 1066 1073 1607913
18. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, Eur Urol 2012 62 3 523 533 10.1016/j.eururo.2012.05.048 22677572
19. ICUD-EAU International Consultation on Bladder Cancer 2012: chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Eur Urol 2013 63 1 58 66 10.1016/j.eururo.2012.08.010 22917984
20. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, J Clin Oncol 2000 18 17 3068 3077 11001674
21. Economic aspects of bladder cancer: what are the benefits and costs? Sievert KD, Amend B, Nagele U, Schilling D, Bedke J, Horstmann M, Hennenlotter J, Kruck S, Stenzl A, World J Urol 2009 27 3 295 300 10.1007/s00345-009-0395-z 19271220
22. Urine cytology discrepancies: frequency, causes, and outcomes. Raab SS, Grzybicki DM, Vrbin CM, Geisinger KR, Am J Clin Pathol 2007 127 6 946 953 10.1309/XUVXFXMFPL7TELCE 17509992